Al/ZnO nanoparticle as an effective nanocarrier in delivery of lenalidomide anti-multiple myeloma cancer drug

References

• Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024 Jan 25;390(4):301–10. doi: 10.1056/NEJMoa2312054
   PubMedGoogle Scholar
• Schoenbeck KL, Wildes TM. Updated perspectives on the management of multiple myeloma in older patients: focus on lenalidomide. Clin Interventions Aging. 2020 May 4;15:619–633. doi: 10.2147/CIA.S196087
   PubMed Web of Science ®Google Scholar
• Alonso R, Cedena MT, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020 May 26;4(10):2163–2171. doi: 10.1182/bloodadvances.2020001508
   PubMed Web of Science ®Google Scholar
• Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Therapeutics. 2008 Jun;33(3):219–226. doi: 10.1111/j.1365-2710.2008.00920.x
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 May 10;366(19):1759–1769. doi: 10.1056/NEJMoa1112704
   PubMed Web of Science ®Google Scholar
• Zhang CW, Wang YN, Ge XL. Lenalidomide use in multiple myeloma. Mol Clin Oncol. 2024 Jan 1;20(1):1–3. doi: 10.3892/mco.2023.2705
   PubMed Web of Science ®Google Scholar
• Jafari AM, Morsali A, Bozorgmehr MR, et al. Modeling and characterization of lenalidomide-loaded tripolyphosphate-crosslinked chitosan nanoparticles for anticancer drug delivery. Int j biol macromol. 2024 Mar 1;260:129360. doi: 10.1016/j.ijbiomac.2024.129360
   PubMed Web of Science ®Google Scholar
• Merz M, Dechow T, Scheytt M, et al. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Ann Hematol.2020 Aug;99(8):1709–1725.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782–1791. doi: 10.1056/NEJMoa1114138
   PubMed Web of Science ®Google Scholar
• Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020 Nov 1;91:22–31. doi: 10.1016/j.exphem.2020.09.196
   PubMed Web of Science ®Google Scholar
• Rao SV, Kumar SS. Lenalidomide loaded polymeric nanoparticles for prostate cancer: a review. Res J Pharm Technol. 2021;14(8):4501–4503. doi: 10.52711/0974-360X.2021.00782
   Google Scholar
• Niknam P, Jamehbozorgi S, Rezvani M, et al. Understanding delivery and adsorption of Lenalidomide drug with ZnONS based on: dispersion-corrected DFT calculations and MD simulations. Physica E Low Dimens Syst Nanostruct. 2022 Jan 1;135:114937. doi: 10.1016/j.physe.2021.114937
   Web of Science ®Google Scholar
• Gong X, Guo L, Zhou R. Exploring the potential use of aluminium nitride nanoparticles in the delivery of lenalidomide anticancer drug. Inorg Chem Commun. 2023 Dec 1;158:111478. doi: 10.1016/j.inoche.2023.111478
   Web of Science ®Google Scholar
• Tan X, Namadchian M, Baghayeri M. Follow up of the prostate cancer treatment based on a novel sensing method for anti-prostate cancer drug (lenalidomide). Environ Res. 2023 Dec 1;238:117261. doi: 10.1016/j.envres.2023.117261
   PubMed Web of Science ®Google Scholar
• Harati H, Morsali A, Bozorgmehr MR, et al. β-cyclodextrin-lenalidomide anticancer drug delivery nanosystem: A quantum chemical approach. J Mol Liq. 2021 Dec 15;344:117762. doi: 10.1016/j.molliq.2021.117762
   Web of Science ®Google Scholar
• Jenner MW, Pawlyn C, Davies FE, et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘myeloma XI’, a multicentre, open‐label, randomised, phase III trial. Br J Haematol. 2023 Apr;201(2):267–279. doi: 10.1111/bjh.18600
   PubMed Web of Science ®Google Scholar
• Du X, Lin Y, Shuai Z, et al. Nanocomposite hydrogel to deliver the immunomodulator lenalidomide and anti-inflammatory hesperidin locally to joints affected by rheumatoid arthritis. Chem Eng J. 2023 Nov 15;476:146270. doi: 10.1016/j.cej.2023.146270
   Web of Science ®Google Scholar
• Arib C, Spadavecchia J. Lenalidomide (LENA) hybrid gold complex nanoparticles: synthesis, physicochemical evaluation, and perspectives in Nanomedicine. ACS Omega. 2020 Oct 30;5(44):28483–28492. doi: 10.1021/acsomega.0c02644
   PubMed Web of Science ®Google Scholar
• Luo Z, Ji L, Liu H, et al. Inhalation lenalidomide-loaded liposome for bleomycin-induced pulmonary fibrosis improvement. AAPS Pharm Sci Tech. 2023 Nov 16;24(8):235. doi: 10.1208/s12249-023-02690-w
   PubMed Web of Science ®Google Scholar
• Mai Z, Cao N, Cheng E, et al. Self-assembled Lenalidomide/AIE prodrug nanobomb for tumor imaging and cancer therapy. ACS Appl Nano Mater. 2023 Oct 18;6(21):19807–19817. doi: 10.1021/acsanm.3c03611
   Web of Science ®Google Scholar
• Quach H, Parmar G, Mateos MV, et al. Recent developments in convenience of administration of the anti-CD38 antibody isatuximab: subcutaneous delivery and fast intravenous infusion in patients with multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2024 Feb 12. doi: 10.1016/j.clml.2024.02.004
   Google Scholar
• Sharifi S, Sheikhi M, Shahab S, et al. DFT study on the interaction of lenalidomide anticancer drug on the Surface of B12N12 Nanocluster. Letters In Organic Chemistry. 2022 Jul 1;19(7):583–595. doi: 10.2174/1570178618666211027102305
   Web of Science ®Google Scholar
• Srinivasan N, Kannan JC. Investigation on room temperature photoluminescence of pure and aluminum doped zinc oxide nanoparticles. Mater Sci-Poland. 2015 Mar 1;33(1):205–212. doi: 10.1515/msp-2015-0021
   Web of Science ®Google Scholar
• Islam MN, Ghosh TB, Chopra KL, et al. XPS and X-ray diffraction studies of aluminum-doped zinc oxide transparent conducting films. Thin Solid Films. 1996 Jul 1;280(1–2):20–25. doi: 10.1016/0040-6090(95)08239-5
   Web of Science ®Google Scholar
• Silva RF, Zaniquelli ME. Morphology of nanometric size particulate aluminium-doped zinc oxide films. Colloids Surf A Physicochem Eng Asp. 2002 Feb 18;198:551–558. doi: 10.1016/S0927-7757(01)00959-1
   Web of Science ®Google Scholar
• Silva RF, Zaniquelli ME. Aluminium doped zinc oxide films: formation process and optical properties. J Non-Crystalline Solids. 1999 Jun 2;247(1–3):248–253. doi: 10.1016/S0022-3093(99)00079-4
   Google Scholar